Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 19/20 | 1.00 |
| ▸ | AR | P10275 | 6/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.59 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4175883 | 0.87 | PGR (1.00) | PGRARNR3C1NR3C2KDM4E | |
| SCHEMBL4189738 | 0.84 | PGR (1.00) | PGRARNR3C1NR3C2KDM4E | |
| SCHEMBL4179126 | 0.83 | PGR (0.71) | PGRARNR3C1NR3C2KDM4E | |
| SCHEMBL4175155 | 0.81 | PGR (0.82) | PGRARNR3C1NR3C2KDM4E | |
| SCHEMBL4170534 | 0.81 | PGR (0.72) | PGRARNR3C1NR3C2KDM4E | |
| SCHEMBL4178875 | 0.80 | PGR (0.81) | PGRARNR3C1NR3C2KDM4E | |
| SCHEMBL4189937 | 0.80 | PGR (0.67) | PGRARNR3C1NR3C2KDM4E | |
| SCHEMBL4180155 | 0.79 | PGR (1.00) | PGRARNR3C1NR3C2KDM4E | |
| SCHEMBL4176428 | 0.79 | PGR (0.78) | PGRARNR3C1NR3C2KDM4E | |
| SCHEMBL4189943 | 0.77 | PGR (1.00) | PGRARNR3C1NR3C2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1382597-A2 | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS, INC. (US) | 2004-01-21 | — | — | EP | claimed |
| EP-1043315-A1 | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2000-10-11 | — | — | EP | claimed |
| CN-1175247-A | Steroid receptor modulator compounds and methods | LIGAND PHARM INC (US) | 1998-03-04 | — | — | CN | claimed |
| US-5688810-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-11-18 | — | — | US | claimed |
| EP-0800519-A1 | STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 1997-10-15 | — | — | EP | claimed |
| WO-1996019458-A2 | STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1996-06-27 | — | — | WO | claimed |
| CN-116334113-A | Conditionally active heterodimeric polypeptides and methods of use thereof | 加利福尼亚大学董事会 | 2023-06-27 | — | — | CN | disclosed |
| CN-109310727-B | Conditionally active heterodimeric polypeptides and methods of use thereof | 加利福尼亚大学董事会 | 2022-09-27 | — | — | CN | disclosed |
| US-20220213452-A1 | CONDITIONALLY ACTIVE HETERODIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-07-07 | — | — | US | disclosed |
| US-20220041687-A1 | A GROUP OF CHIMERIC ANTIGEN RECEPTORS (CARS) | ST. ANNA KINDERKREBSFORSCHUNG (AT) | 2022-02-10 | — | — | US | disclosed |
| US-20210386781-A1 | A GROUP OF CHIMERIC ANTIGEN RECEPTORS (CARS) | UNIVERSITÄT FÜR BODENKULTUR WIEN (AT) | 2021-12-16 | — | — | US | disclosed |
| CN-113286608-A | Chimeric Antigen Receptor (CAR) groups | 圣安娜儿童癌症研究中心 | 2021-08-20 | — | — | CN | disclosed |
| EP-3860643-A1 | A GROUP OF CHIMERIC ANTIGEN RECEPTORS (CARS) | St. Anna Kinderkrebsforschung (AT) | 2021-08-11 | — | — | EP | disclosed |
| US-5696130-A | Tricyclic steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-09 | — | — | US | disclosed |
| US-5693647-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-02 | — | — | US | disclosed |
| US-5693646-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-02 | — | — | US | disclosed |
| US-5688808-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-11-18 | — | — | US | disclosed |
| US-5688810-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-11-18 | — | — | US | disclosed |
| EP-0800519-A1 | STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 1997-10-15 | — | — | EP | disclosed |
| WO-1996019458-A2 | STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1996-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220041687-A1 | A GROUP OF CHIMERIC ANTIGEN RECEPTORS (CARS) | CARS1, CD74, HAVCR2 | PGR 4023/4885AR 554/4885NR3C1 2873/4885 |
| US-20220213452-A1 | CONDITIONALLY ACTIVE HETERODIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF | CPB2, AGBL2, IAPP | PGR 3055/4885AR 3264/4885NR3C1 4406/4885 |
| US-20210386781-A1 | A GROUP OF CHIMERIC ANTIGEN RECEPTORS (CARS) | CD74, HAVCR2, CD2BP2 | PGR 3718/4885AR 377/4885NR3C1 2787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.